[{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"EGYPT","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eva Pharma \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eva Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"EGYPT","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Immunology","graph2":"Approved FDF","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eva Pharma \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eva Pharma \/ Eli Lilly"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"MARC-CRO","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"EGYPT","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Alpha Lipoic Acid","moa":"Lipoyl amidotransferase LIPT1, mitochondrial; Sodium-dependent multivitamin transporter; Lipoyl synthase, mitochondrial","graph1":"Neurology","graph2":"Phase IV","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eva Pharma \/ MARC-CRO","highestDevelopmentStatusID":"11","companyTruncated":"Eva Pharma \/ MARC-CRO"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eva Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alpha Lipoic Acid","moa":"Lipoyl amidotransferase LIPT1, mitochondrial; Sodium-dependent multivitamin transporter; Lipoyl synthase, mitochondrial","graph1":"Nephrology","graph2":"Phase III","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eva Pharma \/ Eva Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Eva Pharma \/ Eva Pharma"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"Structural capsid protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Eva Pharma \/ Eva Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Eva Pharma \/ Eva Pharma"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eva Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"SARS coronavirus 3C-like proteinase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eva Pharma \/ Eva Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Eva Pharma \/ Eva Pharma"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eva Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Revemact","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eva Pharma \/ Eva Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Eva Pharma \/ Eva Pharma"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eva Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Gleptomet","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eva Pharma \/ Eva Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Eva Pharma \/ Eva Pharma"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Veterinary Serum & Vaccine Research Institute, Egypt | The Supreme Council of University Hospitals, Egypt | Ministry of Higher Education and Scientific Research, Egypt","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"EGYPT","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Egyvax Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eva Pharma \/ Veterinary Serum & Vaccine Research Institute, Egypt | The Supreme Council of University Hospitals, Egypt | Ministry of Higher Education and Scientific Research, Egypt","highestDevelopmentStatusID":"6","companyTruncated":"Eva Pharma \/ Veterinary Serum & Vaccine Research Institute, Egypt | The Supreme Council of University Hospitals, Egypt | Ministry of Higher Education and Scientific Research, Egypt"},{"orgOrder":0,"company":"Eva Pharma","sponsor":"Eva Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Eva Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eva Pharma \/ Eva Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Eva Pharma \/ Eva Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Eva Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Humalog (insulin) is a peptide based drug, works by showing agonistic action for GLP-1R, mainly indicated for the treatment of patients with type 1 and 2 diabetes.

                          Product Name : Humalog

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 17, 2024

                          Lead Product(s) : Insulin Lispro

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Eli Lilly

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : The collaboration aims to expand access to Olumiant (baricitinib), an orally-administered, small-molecule, JAK inhibitor, in low- to middle-income countries.

                          Product Name : Olumiant

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 09, 2024

                          Lead Product(s) : Baricitinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved FDF

                          Sponsor : Eli Lilly

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 29, 2024

                          Lead Product(s) : Alpha Lipoic Acid

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Recipient : Ain Shams University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.

                          Product Name : Sunlenca

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 10, 2024

                          Lead Product(s) : Lenacapavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Gilead Sciences

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 14, 2023

                          Lead Product(s) : Alpha Lipoic Acid

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : MARC-CRO

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 05, 2023

                          Lead Product(s) : Gleptomet

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : Genuine Research Center, Egypt

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 08, 2022

                          Lead Product(s) : Nirmatrelvir

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : Genuine Research Center, Egypt

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Lead Product(s) : Egyvax Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase I

                          Sponsor : Veterinary Serum & Vaccine Research Institute, Egypt | The Supreme Council of University Hospitals, Egypt | Ministry of Higher Education and Scientific Research, Egypt

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          February 01, 2022

                          Lead Product(s) : Egyvax Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Veterinary Serum & Vaccine Research Institute, Egypt | The Supreme Council of University Hospitals, Egypt | Ministry of Higher Education and Scientific Research, Egypt

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 13, 2021

                          Lead Product(s) : Metformin

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Undisclosed

                          Recipient : Alexandria University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 22, 2021

                          Lead Product(s) : Revemact

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : Genuine Research Center, Egypt

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank